CATX

Perspective Therapeutics, Inc. · AMEX

Sector Health Technology
Industry Medical Specialties
Website erspectivetherapeutics.com
Employees(FY) 91
ISIN US46489V3024

Performance

-42.17%

-51.23%

-56.43%

-61.44%

+53.48%

YTD

+149.6%

Profile

Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.

Advanced Technical Analysis

Technical Analysis of CATX 2024-11-20

The stock indicators reflect a bearish sentiment, with the Moving Average Score at 10, Oscillators Score at 36, and a Technical Score of 23, indicating overall weakness in price momentum and suggesting caution for potential investors. The low scores across all categories highlight a lack of bullish signals in the current market environment.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of CATX

Stock Rank

Recent News & Updates

2024-11-16 01:26
Is Perspective Therapeutics (CATX) the Best Multibagger Stock to Buy Heading into 2025?(Insider Monkey)
2024-11-15 16:08
Perspective Therapeutics to Discuss Data on [212Pb]VMT-α-NET Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium on November 21, 2024(GlobeNewswire)
2024-11-15 03:08
Perspective Therapeutics to Discuss Data on [212Pb]VMT-a-NET Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium on November 21, 2024(Globenewswire)
2024-11-15 03:08
Perspective Therapeutics to Discuss Data on [212Pb]VMT- -NET Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium on November 21, 2024(Globenewswire)
2024-11-13 08:01
RBC Trims Price Target on Perspective Therapeutics to $25 From $27, Keeps Outperform, Speculative Risk(MT Newswires)
2024-11-12 16:37
Perspective Therapeutics: Q3 Earnings Snapshot(Associated Press Finance)
2024-11-12 16:05
Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 3Q 2024 Results(GlobeNewswire)
2024-11-12 03:05
Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 3Q 2024 Results(Globenewswire)
2024-10-31 07:00
Perspective Therapeutics to Provide Business Highlights and Report Third Quarter 2024 Financial Results(GlobeNewswire)
2024-10-30 19:00
Perspective Therapeutics to Provide Business Highlights and Report Third Quarter 2024 Financial Results(Globenewswire)
2024-10-29 07:00
Perspective Therapeutics to Participate in Upcoming Investor Conferences in November(GlobeNewswire)
2024-10-28 19:00
Perspective Therapeutics to Participate in Upcoming Investor Conferences in November(Globenewswire)
2024-10-24 11:12
UBS Initiates Perspective Therapeutics at Buy With $20 Price Target(MT Newswires)
2024-10-23 07:00
Perspective Therapeutics Presents Updates at the 37th Annual Congress of the European Association of Nuclear Medicine(GlobeNewswire)
2024-10-22 19:00
Perspective Therapeutics Presents Updates at the 37th Annual Congress of the European Association of Nuclear Medicine(Globenewswire)
2024-10-16 11:01
Perspective Therapeutics Makes First Shipment of Investigational Products From New Jersey Facility(MT Newswires)
2024-10-16 07:00
Perspective Therapeutics Begins Shipping Investigational Products from State-of-the-Art Radiopharmaceutical Manufacturing Facility in Somerset, New Jersey(GlobeNewswire)
2024-10-12 10:18
Perspective Therapeutics, Inc (CATX): A Small-Cap Pioneer in Targeted Cancer Therapies(Insider Monkey)
2024-10-11 12:16
Wedbush Adjusts Price Target on Perspective Therapeutics to $20 From $25, Maintains Outperform Rating(MT Newswires)
2024-10-11 09:23
Perspective Therapeutics Says Initial Data Show Potential Melanoma Therapy's Safety, Efficacy(MT Newswires)
2024-10-11 08:30
Perspective Therapeutics to Advance Investigation of Potential First-In-Class Radiopharmaceutical Therapy [212Pb]VMT01 Based on Data Presented at the 21st International Congress of the Society for Melanoma Research(GlobeNewswire)
2024-10-10 17:14
Perspective Therapeutics to Present at the 21st International Congress of the Society for Melanoma Research(GlobeNewswire)
2024-10-10 05:14
Perspective Therapeutics to Present at the 21st International Congress of the Society for Melanoma Research(Globenewswire)
2024-10-07 07:00
Perspective Therapeutics to Participate at the Oppenheimer Targeted Radiopharmaceutical Therapies in Oncology Summit & JonesResearch Virtual Radiopharma Day(GlobeNewswire)
2024-10-06 19:00
Perspective Therapeutics to Participate at the Oppenheimer Targeted Radiopharmaceutical Therapies in Oncology Summit & JonesResearch Virtual Radiopharma Day(Globenewswire)
2024-10-01 07:02
Wedbush Initiates Perspective Therapeutics at Outperform With $25 Price Target(MT Newswires)
2024-09-30 07:00
Perspective Therapeutics to Present at the 37th Annual Congress of the European Association of Nuclear Medicine(GlobeNewswire)
2024-09-29 19:00
Perspective Therapeutics to Present at the 37th Annual Congress of the European Association of Nuclear Medicine(Globenewswire)
2024-09-25 07:31
Update: Truist Initiates Perspective Therapeutics at Buy With $21 Price Target(MT Newswires)
2024-09-25 07:03
Truist Initiates Perspective Therapeutics at Buy(MT Newswires)

Page 1 of 5

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.